{"id":15658,"date":"2023-07-28T12:24:00","date_gmt":"2023-07-28T04:24:00","guid":{"rendered":"https:\/\/flcube.com\/?p=15658"},"modified":"2024-12-10T10:50:21","modified_gmt":"2024-12-10T02:50:21","slug":"msds-v116-vaccine-shows-superior-immune-response-in-phase-iii-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=15658","title":{"rendered":"MSD’s V116 Vaccine Shows Superior Immune Response in Phase III Trials"},"content":{"rendered":"\n

Merck, Sharp & Dohme (MSD; NYSE: MRK<\/a>) has revealed positive topline results from two Phase III trials assessing the company’s 21-valent pneumococcal conjugate vaccine candidate, V116. This vaccine, the first of its kind designed for use in adults, is being evaluated in a comprehensive clinical trial program involving 2,600 patients.<\/p>\n\n\n\n

STRIDE-3 Trial Outcomes<\/strong>
In the STRIDE-3 head-to-head trial against Pfizer\u2019s 20-valent conjugate vaccine, Prevnar, V116 demonstrated significantly improved immune responses. The study compared the efficacy of V116 against Prevnar and found that MSD’s candidate provided a more robust immune response, which is a significant advancement in the field of pneumococcal vaccination.<\/p>\n\n\n\n

STRIDE-6 Trial Safety and Immunogenicity<\/strong>
The STRIDE-6 study, which assessed the safety, tolerability, and immunogenicity of V116 in over 700 adults, showed that V116 was immunogenic for all 21 pneumococcal serotypes included in the vaccine. This was observed among adults who had previously received a pneumococcal vaccine at least one year prior to the study, indicating the potential for V116 to provide additional protection to those already vaccinated.<\/p>\n\n\n\n

Unique Serotypes Covered by V116<\/strong>
V116 includes eight serotypes not currently covered by approved pneumococcal vaccines, offering the potential for broader protection against invasive pneumococcal disease. Serotypes unique to V116, such as 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B, were responsible for approximately 30% of invasive pneumococcal disease in individuals aged 65 and older, based on pre-pandemic 2019 CDC data. This highlights the potential impact of V116 in reducing the disease burden in vulnerable populations.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed positive topline results from two Phase…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[120,2675,176,903],"class_list":["post-15658","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-merck","tag-merck-sharp-dohme","tag-msd","tag-nyse-mrk"],"yoast_head":"\nMSD's V116 Vaccine Shows Superior Immune Response in Phase III Trials - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed positive topline results from two Phase III trials assessing the company's 21-valent pneumococcal conjugate vaccine candidate, V116. This vaccine, the first of its kind designed for use in adults, is being evaluated in a comprehensive clinical trial program involving 2,600 patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=15658\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MSD's V116 Vaccine Shows Superior Immune Response in Phase III Trials\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=15658\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-28T04:24:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-10T02:50:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15658#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15658\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"MSD’s V116 Vaccine Shows Superior Immune Response in Phase III Trials\",\"datePublished\":\"2023-07-28T04:24:00+00:00\",\"dateModified\":\"2024-12-10T02:50:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15658\"},\"wordCount\":258,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Merck\",\"Merck Sharp & Dohme\",\"MSD\",\"NYSE: MRK\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15658#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15658\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=15658\",\"name\":\"MSD's V116 Vaccine Shows Superior Immune Response in Phase III Trials - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-07-28T04:24:00+00:00\",\"dateModified\":\"2024-12-10T02:50:21+00:00\",\"description\":\"Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed positive topline results from two Phase III trials assessing the company's 21-valent pneumococcal conjugate vaccine candidate, V116. This vaccine, the first of its kind designed for use in adults, is being evaluated in a comprehensive clinical trial program involving 2,600 patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15658#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15658\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15658#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MSD’s V116 Vaccine Shows Superior Immune Response in Phase III Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MSD's V116 Vaccine Shows Superior Immune Response in Phase III Trials - Insight, China's Pharmaceutical Industry","description":"Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed positive topline results from two Phase III trials assessing the company's 21-valent pneumococcal conjugate vaccine candidate, V116. This vaccine, the first of its kind designed for use in adults, is being evaluated in a comprehensive clinical trial program involving 2,600 patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=15658","og_locale":"en_US","og_type":"article","og_title":"MSD's V116 Vaccine Shows Superior Immune Response in Phase III Trials","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=15658","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-07-28T04:24:00+00:00","article_modified_time":"2024-12-10T02:50:21+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=15658#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=15658"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"MSD’s V116 Vaccine Shows Superior Immune Response in Phase III Trials","datePublished":"2023-07-28T04:24:00+00:00","dateModified":"2024-12-10T02:50:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=15658"},"wordCount":258,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Merck","Merck Sharp & Dohme","MSD","NYSE: MRK"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=15658#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=15658","url":"https:\/\/flcube.com\/?p=15658","name":"MSD's V116 Vaccine Shows Superior Immune Response in Phase III Trials - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-07-28T04:24:00+00:00","dateModified":"2024-12-10T02:50:21+00:00","description":"Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed positive topline results from two Phase III trials assessing the company's 21-valent pneumococcal conjugate vaccine candidate, V116. This vaccine, the first of its kind designed for use in adults, is being evaluated in a comprehensive clinical trial program involving 2,600 patients.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=15658#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=15658"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=15658#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"MSD’s V116 Vaccine Shows Superior Immune Response in Phase III Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15658","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15658"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15658\/revisions"}],"predecessor-version":[{"id":15659,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15658\/revisions\/15659"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15658"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15658"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15658"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}